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Propionibacterium acnes is a key therapeutic target in acne, yet this bacterium has become resistant to standard
antibiotic agents. We investigated whether the human antimicrobial protein granulysin is a potential candidate for
the treatment of acne. Granulysin and synthetic granulysin-derived peptides possessing a helix–loop–helix motif
killed P. acnes in vitro. Modiﬁcation of a helix–loop–helix peptide, 31–50, by substitution of a tryptophan for the
valine at amino acid 44 (peptide 31–50v44w) to increase its interaction with bacterial surfaces also increased its
antimicrobial activity. Moreover, when synthesized with D- rather than L-type amino acids, this peptide (D-31–
50v44w) became less susceptible to degradation by proteases and more effective in killing P. acnes. Granulysin
peptides were bactericidal, demonstrating an advantage over standard bacteriostatic antibiotics in their control of
P. acnes. Moreover, peptide D-31–50v44w killed P. acnes in isolated human microcomedone preparations. Impor-
tantly, peptides 31–50, 31–50v44w, and D-31–50v44w also have potential anti-inﬂammatory effects, as demonstrated
by suppression of P. acnes-stimulated cytokine release. Taken together, these data suggest that granulysin pep-
tides may be useful as topical therapeutic agents, providing alternatives to current acne therapies.
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Since their introduction approximately 60 y ago, antibiotics
have been our most powerful weapons against microbial
invaders. The effectiveness of traditional antibiotics has,
however, been severely limited by the development of mul-
tidrug-resistant bacterial strains. In particular, analysis of
clinical isolates of Propionibacterium acnes, a major etio-
logic agent of acne vulgaris, has indicated increasing re-
sistance to standard antibiotic therapies, making the
treatment of acne more challenging (Cooper, 1998; Coates
et al, 2002; Ross et al, 2003). Thus, there is a need for the
development of new antimicrobial agents for the treatment
of acne and other diseases with an infectious component.
Throughout evolution, single and multicellular organisms
evolved host defense mechanisms that combat bacterial
infections. These include endogenous antimicrobial pep-
tides, a major mechanism of host defense, capable of both
killing microbes and modulating the host’s immune re-
sponse. Granulysin is an antimicrobial peptide of the sapo-
sin-like family, a family of peptides that has been conserved
from amoebas to humans and has been shown to be
important in host defense of the skin (Ochoa et al, 2001).
Our analysis of acne lesions demonstrated the presence of
granulysin in inflammatory T cells, yet not in the piloseba-
ceous units where P. acnes resides. Other studies have de-
scribed the presence of T cells in both early and late acne
lesions, demonstrating the importance of T cells in the bi-
ology of acne.
We hypothesized that granulysin, representing a natural
form of host defense in cutaneous infection, may be useful
as a topical agent in the treatment of acne. We sought to
explore the effectiveness of granulysin and granulysin-de-
rived peptides in killing P. acnes in vitro, both in standard
microbiologic assays and in human-derived microcomed-
ones. Moreover, since P. acnes has been shown to trigger
pro-inflammatory responses (Vowels et al, 1995; Kim et al,
2002) and since current antibiotics are thought to exert both
antimicrobial and anti-inflammatory effects, we also sought
to determine whether granulysin-derived peptides had the
ability to inhibit P. acnes-induced cytokine release.
Results
Granulysin and granulysin peptides have antimicrobial
activity against P. acnes We hypothesized that antimicro-
bial proteins, having a broad spectrum of activity and being1Present address: Explora BioLabs, La Jolla, California, USA.
Abbreviations: MBC, minimum bactericidal concentration; TLR,
Toll-like receptor
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naturally present during acne, might be effective in com-
bating P. acnes, a major therapeutic target in acne. One
such protein is granulysin, which is localized in cytotoxic
granules of NK and T cells and kills both Gram-positive and
Gram-negative bacteria (Stenger et al, 1998). To determine
whether the antimicrobial protein granulysin kills P. acnes,
we tested the activity of recombinant human granulysin
against P. acnes using the CFU assay. Granulysin exhibited
antimicrobial activity in a concentration-dependent manner,
reducing the number of P. acnes CFU by approximately 4
logs (to less than 5% maximum growth) at a concentration
of 32 mM, whereas a control peptide derived from HSP70
had no effect (Fig 1A).
The crystal structure of granulysin reveals that it contains
five alpha helical domains, and the ability of granulysin to kill
Salmonella typhimurium and Escherichia coli has been lo-
calized to regions of granulysin that include helices 2 or 3
(Ernst et al, 2000; Wang et al, 2000; Anderson et al, 2003).
Therefore, we synthesized peptides based on the sequence
of granulysin, some of which included these regions. Two
peptides containing helix–loop–helix domains and corre-
sponding to amino acid residues 1–35 and 31–50 were
found to reduce the number of viable P. acnes; these pep-
tides killed P. acnes in a concentration-dependent manner
with 100 mM of peptide reducing the number of viable P.
acnes by 2 and 4 logs, respectively, to less than 1% of
maximum growth (Fig 1B). In contrast, four non-helix–loop–
helix peptides (peptides 1–20, 16–35, 46–65, and 61–80)
had little or no antimicrobial activity and reduced the
number of viable P. acnes by o1 log without effecting the
% maximum growth (Fig 1C). In whole, these data indicate
that granulysin can kill P. acnes, and its antimicrobial ac-
tivity can be localized to a smaller region of the molecule
with a defined structural motif, the helix–loop–helix.
Modiﬁcation of a granulysin peptide enhances its anti-
microbial activity We next sought to determine whether
modifications to peptide 31–50 could enhance its antimi-
crobial activity. As amino acid 44 resides in a scissor-like
pocket between helices 2 and 3, we hypothesized that
substitution at this position to create a hydrophobic anchor
for the peptide in the bacterial surface would enhance kill-
ing. Our modeling indicated that substituting the valine at
position 44 with a tryptophan (31–50v44w) would increase
the Fauchere and Pliska hydrophobicity from 0.3 to 0.7.
As a positive Fauchere & Pliska hydrophobicity correlates
with strong antimicrobial activity, we predicted peptide
31–50v44w would have enhanced activity. Moreover, try-
ptophans have been found in proteins that cross mem-
branes and have been shown to be important for the activity
of other antimicrobial peptides (Qi and Grabowski, 2001;
Fimland et al, 2002). We therefore compared the antimicro-
bial activity of 31–50v44w to 31–50. Incubation with 32 mM
of peptide 31–50v44w resulted in 2–3 logs fewer bacteria
(with greater than 50 times the maximum growth inhibition)
as compared to incubation with the peptide 31–50; the en-
hanced antimicrobial activity of 31–50v44w was evident
over peptide concentrations ranging from 8 to 100 mM and
was concentration-dependent (Fig 2A). This demonstrates
that modifications to increase peptide hydrophobicity may
also increase the antimicrobial activity of the peptide.
Granulysin peptide 31–50v44w alters the surface of P.
acnes Granulysin exerts its antimicrobial activity against
the Gram-negative bacterium E. coli by disturbing the in-
tegrity of the cell membrane (Ernst et al, 2000). To determine
if a similar mechanism is employed in the killing of P. acnes,
a Gram-positive organism, by granulysin peptides, we ex-
amined bacteria that had been treated with 31–50v44w us-
ing both scanning EM and transmission EM. Both, scanning
and transmission EM micrographs of untreated P. acnes
illustrate the bacterium’s normal pleomorphic structure. By
scanning EM, the surface of the untreated bacteria ap-
peared smooth and rounded with fimbriae present, whereas
the peptide-treated bacteria demonstrated a recessed and
withered surface with an absence of fimbriae (Fig 2B).
Figure1
Granulysin and granulysin peptides have antimicrobial activity
against Propionibacterium acnes. (A) Various concentrations (0–100
mM) of recombinant granulysin were incubated with P. acnes for 4 h and
tested for antimicrobial activity using the CFU assay (left, represent-
ative experiment; right, average % maximum growth  SEM, n¼ 8). (B)
Synthetic peptides of granulysin predicted to conform to a helix–loop–
helix motif (residues 1–35, 36–70, and 31–50) and the 9-kDa granulysin
were incubated with P. acnes at various concentrations (0–100 mM) for
4 h and the antimicrobial activity was determined by CFU assay (left,
representative experiment; right, average % maximum growth  SEM,
n¼ 3). (C) Additional synthetic granulysin peptides (residues 1–20, 16–
35, 46–65, and 61–80) were compared with the 9-kDa granulysin for
antimicrobial activity by CFU assay (left, representative experiment;
right, average % maximum growth  SEM, n¼ 3).
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Similarly, differences between untreated and peptide-treat-
ed bacteria were appreciated by low magnification trans-
mission EM, which demonstrated many ‘‘ghost’’ cells after
72 h of peptide treatment and few surviving bacteria with
darker and more condensed cytoplasms compared to un-
treated bacteria. Higher magnification transmission EM
revealed the untreated P. acnes had a cell wall with well-
demarcated outer and inner dark, lipophilic layers and a
lighter, hydrophilic peptidoglycan layer. In contrast, after
only 1 h of incubation with 31–50v44w, P. acnes lost the
integrity of this surface architecture as the lighter, more hy-
drophilic, peptidoglycan layer as well as the darker more
lipophilic layers of the cell wall appear disturbed, losing their
crisp, well-defined structures (Fig 2C). In addition, we ob-
served a wider, likely edematous, space inside of the cell
wall, further suggesting its disruption as well as peripheral
clumping of nuclear material within the cell. In whole, these
images reveal that peptide 31–50v44w perturbs the surface
integrity of P. acnes in a manner that may make it porous,
suggesting that this is the likely mechanism by which gran-
ulysin peptides kill this organism.
Further modiﬁcation of 31–50v44w generates a peptide
with greater antimicrobial activity Since naturally occur-
ring peptides exist in L-conformations and are susceptible
to proteases, we synthesized a more stable peptide with the
sequence 31–50v44w by using only D-type amino acids (D-
31–50v44w) as they have been shown to be more protease-
resistant (Alvarez-Bravo et al, 1994). We then tested this
peptide against a wild-type strain of E. coli (TOP10) and a
protease-deficient mutant strain of E. coli (ATCC 55099) to
determine if greater peptide stability would enhance anti-
microbial activity. Peptide D-31–50v44w was equally effec-
tive as L-31–50v44w in killing the protease-deficient strain of
E. coli. The minimum bactericidal concentration (MBC) of D-
31–50v44w against the wild-type, protease-positive strain
of E. coli was, however, only 2 mM whereas that of L-31–
50v44w was 16 mM (Fig 3A). Additional studies demon-
strated that D-31–50v44w exhibited great potency against
P. acnes in vitro; treatment with as little as 32 mM of this
peptide resulted in a 5 log reduction (to less than 0.01%
maximum growth) in viable P. acnes by CFU assay (Fig 3B).
Granulysin peptides are superior antimicrobials com-
pared to antibiotics currently used to treat acne In com-
paring the antimicrobial activity of the granulysin peptides
against that of widely used antibiotics, we found that tet-
racycline and clindamycin were bacteriostatic, preventing
the further growth of P. acnes. On the other hand, peptide
D-31–50v44w was bactericidal, capable of potently de-
creasing the number of viable P. acnes (Fig 3C). Thus,
granulysin peptides have an efficacy advantage over stand-
ard antibiotics in the control of P. acnes.
D-31–50v44w demonstrates antimicrobial activity in hu-
man microcomedone isolates The earliest subclinical
acne ‘‘lesion’’ is a microcomedone, which consists of
keratinized material, lipids such as squalene, cholesterol,
cholesterol esters, wax esters, and triglycerides, and P. ac-
nes. In order to demonstrate that granulysin peptides main-
tain their antimicrobial activity within this lipid-rich
environment and against strains of P. acnes present within
the community, we have isolated microcomedones from
human donors as an in vitro model for the efficacy of an-
timicrobial peptides. We tested the antimicrobial activity of
D-31–50v44w against clinical isolates of P. acnes using mi-
crocomedone isolates. Indeed, D-31–50v44w was effective
in killing P. acnes in sebaceous microcomedome extracts
(Fig 4). Importantly, this demonstrates not only that this
peptide is an effective bactericidal agent within sebaceous
environments, but also that strains of P. acnes present in
the community are susceptible to this peptide.
Figure 2
Modification of a granulysin peptide to enhance its antimicrobial
activity. The antimicrobial effect of a structure-function modification to
a granulysin peptide was determined. A hydrophobic residue, try-
ptophan, was added to the granulysin peptide 31–50 to create an an-
chor for the peptide in the bacterial surface. (A) Peptides 31–50 and 31–
50v44w were then incubated with P. acnes and tested for antimicrobial
activity by CFU assay (left, representative experiment; right, average %
maximum growth  SEM, n¼5), (B) SEM and low power TEM (10K
magnification), demonstrated the effect of 31–50v44w (20 mM) on the
surface of P. acnes after incubation for 72 h as compared to the surface
of untreated control bacteria. (C) At higher power (36K magnification),
peptide treatment (20 mM) was shown to disturb the sharply layered
surface architecture of P. acnes, making the cell wall less distinct and
more permeable to fluid influx. EM studies represent data from three
different experiments.
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Anti-inﬂammatory effects of an antimicrobial granulysin
peptide An important component of acne is the inflamma-
tory response elicited by P. acnes. Primary human mon-
ocytes stimulated with P. acnes secreted a wide variety
of inflammatory cytokines and chemokines including
IL-12p40, IL-12p70, IL-6, IL-8, MCP-1, IP-10, MIP-1a,
MIP-3a, MDC, and ITAC (data not shown). The production
of these cytokines and chemokines may play important
roles in the formation of inflammatory acne lesions (Vowels
et al, 1995; Kim et al, 2002). For instance, the induction of
Figure 3
Antimicrobial effects of granulysin pep-
tides with D- and L-type amino acids. (A)
Granulysin peptides with the sequence
31–50v44w were synthesized using only
D-type amino acids (D-31–50v44w) or L-
type amino acids (L-31–50v44w) and in-
cubated with a wild-type strain of Es-
cherichia coli or a mutant strain of E. coli,
and the minimum bactericidal concentra-
tion was determined. (B) Granulysin
peptides with D-type amino acids (D-31–
50v44w) or L-type amino acids (L-31–
50v44w) were incubated with P. acnes
and the antimicrobial activity was de-
termined using CFU assay (left, repre-
sentative experiment; right, average %
maximum growth  SEM, n¼4). (C) The
antimicrobial activity of granulysin peptide
D-31–50v44w was compared to tetracy-
cline and clindamycin in a qualitative CFU
assay which involved plating antibiotics
and peptides with P. acnes on solid media
and counting individual colonies to deter-
mine the CFU. Experiments in (A) and
(C) are representative of two or more
experiments.
Figure 4
Antimicrobial effects of a granulysin
peptide within the sebaceous micro-
comedone environment. Granulysin pep-
tide D-31–50v44w was incubated with
Propionibacterium acnes in a collection
of lipid-rich microcomedones isolated
from donors’ faces using pore cleasing
strips, and the antimicrobial activity was
determined using the CFU assay.
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IL-8 by P. acnes may help recruit neutrophils to the skin,
promoting pustule formation.
Given that antimicrobial peptides have been shown to
have immunomodulatory effects (Territo et al, 1989; Van
Wetering et al, 1997; Lentsch et al, 1999; Lillard et al, 1999;
Yang et al, 1999; Scott et al, 2000, 2002), we determined
whether peptide 31–50v44w could alter P. acnes-stimulated
production of cytokines and chemokines from primary
human monocytes. Importantly, 31–50v44w decreased P.
acnes-stimulated production of IL-12p40, as compared to
the non-helix-loop-helix peptides 1–20 and 16–35 (Fig 5A).
In addition, peptide 31–50v44w inhibited the production of
several chemokines, including MCP-1, IP-10, and MDC,
from P. acnes-stimulated monocytes (Figs 5B–D). 31–
50v44w, however, demonstrated little to no inhibition of
IL-6 and IL-8 by P. acnes stimulated monocytes (data not
shown). Furthermore, granulysin peptide D-31–50v44w also
decreased P. acnes-stimulated production of cytokines and
chemokines (data not shown).
Discussion
The increased incidence of drug resistance in clinical isolates
of bacteria has underscored the need to identify new ther-
apeutic agents. This issue is of particular importance in the
treatment of P. acnes, a bacteria implicated in the patho-
genesis of acne, since the increase in frequency of resistant
strains is becoming a major clinical issue (Cooper, 1998;
Coates et al, 2002; Ross et al, 2003). Since our immune sys-
tem utilizes antimicrobial peptides to effectively combat in-
fection, we hypothesized that these molecules may be
suitable drug candidates. The ideal therapy for acne would
be a potent antimicrobial agent with anti-inflammatory prop-
erties that maintains stability in the lipid-rich cutaneous envi-
ronment. In this paper, we provide evidence that one such
candidate, a modified granulysin peptide, effectively kills P.
acnes in vitro, both in the growth media and in sebaceous
units. Moreover, our data demonstrate that in contrast to tet-
racycline and clindamycin, bacteriostatic agents currently
used to treat acne, granulysin peptides are bactericidal.
Finally, these peptides demonstrate anti-inflammatory proper-
ties through their reduction of P. acnes-stimulated production
of cytokines and chemokines. The combined antimicrobial and
anti-inflammatory activity of granulysin-derived peptides make
them logical therapeutic agents for the treatment of acne.
The secondary structure of an antimicrobial peptide has
been shown to be essential for maintenance of its anti-
microbial activity. Previous studies by Wang et al (2000)
demonstrated that peptides based on the sequence of
granulysin that contained segments of either helix 2 (amino
acids 23–36) or helix 3 (amino acids 42–51) were capable of
lysing bacteria, identifying these regions as important for
antimicrobial activity against S. typhimurium (Wang et al,
2000). Furthermore, our earlier study demonstrated that
peptides corresponding to amino acid residues 1–35,
31–50, and 36–70, which contain helix–loop–helix structures
Figure 5
The immunomodulatory effect of granulysin peptides. Granulysin peptide 31–50v44w (5 mM) was incubated with primary human monocytes
which were subsequently stimulated with Propionibacterium acnes sonicate. (A) IL-12p40 levels were determined by ELISA using triplicates (left,
representative experiment; right, average % activation of IL-12p40 by P. acnes  SEM, n¼12). The chemokines (B) MCP-1, (C) IP-10, and (D) MDC
levels were determined by cytokine array (Pierce SearchLight Multiplex). (left, representative experiment; right, average % activation  SEM of two
independent experiments each assayed by array twice, n¼4).
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were capable of killing both E. coli and Mycobacterium tu-
berculosis, whereas those peptides that did not contain this
secondary structure were incapable of bacterial killing (Ernst
et al, 2000). Similarly, here we provide evidence that gran-
ulysin peptides with helix–loop–helix structures, peptides 1–
35 and 31–50, are effective at killing P. acnes. Additionally, it
may be possible to design even shorter granulysin peptides
with enhanced antimicrobial activity (Hamamoto et al, 2002).
An ideal topical antimicrobial therapy must be both potent
in activity and stable to the cutaneous environment. We have
modified the granulysin peptide 31–50 in two different ways
to address these characteristics. First, we substituted the
valine at amino acid position 44 for a tryptophan and created
a peptide (31–50v44w) with enhanced antimicrobial activity
against P. acnes. Since tryptophan residues have the ability
to penetrate membranes, their presence in antimicrobial
peptides has been correlated with antimicrobial activity (Fim-
land et al, 2002). For instance, NK-lysin, a member of the
saposin-like protein family along with granulysin, has antimi-
crobial activity and has been shown to partially insert its try-
ptophan in membranes (Qi and Grabowski, 2001). Similarly,
the native granulysin protein has one tryptophan at amino
acid position 41 on helix 3, a highly lytic segment. Our EM
studies document the ability of 31–50v44w to disrupt bac-
terial surface architecture. Although we do not show that
there is a direct interaction between the tryptophan residues
and the bacteria, the potent antimicrobial activity of this
modified peptide suggests that tryptophans are indeed im-
portant for antimicrobial activity against P. acnes.
We next made an additional modification to granulysin
peptide 31–50 to enhance its stability to proteases from
both bacteria and human skin. We synthesized 31–50v44w
entirely with D-type amino acids (D-31–50v44w) and found
this peptide exhibited even greater potency in vitro as com-
pared to 31–50v44w. Our experiments with E. coli demon-
strated that the D versus L form of 31–50v44w exhibited
increased antimicrobial potency due to its protease-resist-
ance. This corroborates the findings in the study of Alvarez-
Bravo et al (1994), which found that the D-form of a sapecin
B-derived peptide was able to avoid degradation by trypsin.
Based on the enhanced activity and stability of these mod-
ified peptides, it is possible that additional modifications
may even further improve their antimicrobial utility.
A key feature of effective anti-acne agents is their ability
to maintain antimicrobial activity within the lipid-rich envi-
ronment of the pilosebaceous unit. Since the earliest acne
‘‘lesion’’ is a microcomedone, sampling of microcomedones
has been used for assessment of microbial colonization
(Holland and Roberts, 1974) and the efficacy of antimicro-
bial therapy in acne (Pierard-Franchimont et al, 2002). Mi-
crocomedones removed with cyanoacrylate strips are
‘‘follicular casts’’ containing a mixture of keratinized mate-
rial, cell debris, lipids, and bacteria (Thielitz et al, 2001).
Therefore, in order to test the efficacy of granulysin peptides
against clinical isolates of P. acnes and within lipid-rich en-
vironments, we used pore strips to extract P. acnes and
other follicular contents from human donors for use in an
in vitro assay. Our results of this assay demonstrate peptide
D-31–50v44w maintains its antimicrobial activity against clin-
ical isolates and within sebaceous environments, suggesting
its promise in acne therapy. Furthermore, experiments in our
lab indicate these peptides have minimal effect on the via-
bility of both HaCaT and human monocytes (unpublished
data), suggesting that they may not only be efficacious an-
timicrobials but also safe topical agents.
Antimicrobial peptides have been shown to have
immunomodulatory functions. Here we show that granu-
lysin peptides 31–50v44w and D-31–50v44w inhibit the
production of inflammatory cytokines and chemokines by
P. acnes-stimulated monocytes. P. acnes is a potent
stimulator of host immune responses, and since inflamma-
tion is a key clinical feature of acne, the anti-inflammatory
nature of these peptides increases their therapeutic poten-
tial. Previously, it has been shown that LL-37 decreases
cytokine production in response to LPS, a Toll-like receptor
4 (TLR4) ligand (Scott et al, 2002). Here, we show that
granulysin peptides decrease cytokine production in
response to P. acnes, which stimulates cells through
TLR2 (Kim et al, 2002). Although the precise anti-inflamma-
tory mechanism is not known, it is possible that the pep-
tides are interfering with aspects of the TLR2 pathway, such
as the activation of NFkB. On the other hand, the peptide
may be interacting with and binding up TLR ligands present
in P. acnes sonicates, preventing some of these compo-
nents from activating TLR. Furthermore, since P. acnes
contain a unique peptidoglycan, N-acetylmuramic acid-L-
alanine-D-glutamate-L, L-diaminopimelic acid within the cell
wall (Kamisango et al, 1982), it is possible that cytokine
production may occur through the intracellular peptidogly-
can receptors Nod1 or Nod2 which recognize similar motifs.
Since P. acnes may contain ligands for Nods as well as
TLR, blocking of either of these pathways may explain the
diminution of cytokine and chemokine production. Our cur-
rent studies are exploring these potential mechanisms.
In this paper, we have demonstrated that an endogenous
antimicrobial peptide, granulysin, can be a novel therapeu-
tic agent in treating acne, one of the most common der-
matologic conditions affecting over 85% of the population.
The bactericidal and anti-inflammatory properties of gran-
ulysin peptides make them ideal candidates for the treat-
ment of acne. Furthermore, we have demonstrated that
modification of granulysin peptides can lead to more stable
peptides that maintain their antimicrobial activity in the lipid-
rich environment of microcomedones.
Whether granulysin peptides will be effective in clinical
settings is not yet certain as there are no animal models for
acne. Furthermore, it is possible that novel peptides pro-
duced from significant modifications to endogenous pep-
tides may activate the host immune response. Therefore, it
may be wise for us to use natural peptides for clinical ap-
plications. Future clinical trials in humans will determine the
outcome of their use. Certainly, the broad spectrum of ac-
tivity increases the utility of granulysin peptides as they may
be effective in treating other cutaneous infections caused
by resistant bacteria.
Methods
Production and puriﬁcation of recombinant granulysin Granuly-
sin was produced in E. coli BL21 (DE3) transformed with the
kanamycin-selective vector, pET28, containing a hexahistidine fusion
tag (Novagen, Madison, Wisconsin) as previously described (Pena
et al, 1997; Ernst et al, 2000). The transformed E. coli were grown in
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2  YT broth and induced with 1 mM isopropyl-b-D-thiogalactoside
(Fisher Scientific, Pittsburgh, Pennsylvania). The bacteria were har-
vested and denatured in 6 M guanidine HCl/0.05 mM Tris HCl pH 7.4.
Granulysin was purified via nickel affinity chromatography according
to the manufacturer’s recommendation (Qiagen, Valencia, California)
and eluted with 0.2 M imidazole, then reduced with 10 mM DTT. The
denatured granulysin was re-natured in 0.75 M arginine, 0.05 M Tris
HCl pH 8.0, 0.05 M KCl, 0.1 mM EDTA, and 10 mM oxidized DTTat a
1:5 dilution with constant stirring for 48 h at 41C. The re-natured
protein was then dialyzed against a buffer containing 2 mM sodium
phosphate and 13 mM sodium chloride pH 7.2, then lyophilized. The
granulysin pellet was rehydrated and treated with thrombin for 16 h to
cleave the hexahistidine tag. Following thrombin cleavage, the protein
was loaded onto a Rainin C18 reverse phase chromatography column
(Braintree, Massachusetts) and eluted by a linear gradient of 10%–
60% aqueous acetonitrile in 0.1% trifluoroacetic acid. The fractions
containing granulysin, as determined by Coomassie staining of a
15% SDS-PAGE gel, were lyophilized then hydrated in 10 mM so-
dium phosphate pH 7.2 unless otherwise noted. The final protein
concentration was determined using the bicinchoninic acid protein
assay (Pierce, Rockford, Illinois) with bovine serum albumin as a
standard. Protein purity was assessed by Coomassie staining of 15%
SDS-PAGE gels and was 495%. Additionally, purified granulysin
was analyzed by matrix-assisted laser desorption ionization mass
spectrometry and shown to contain one species at 9081 Da that
corresponded to the calculated mol wt, which is 9070.4 assuming
that four of the five cysteines are involved in disulfide bridges.
Peptide synthesis Peptides encompassing the entire amino acid
sequence of granulysin were synthesized using F-moc chemistry
by either an Applied Biosystems (Foster City, California) or UCLA
Peptide Core (Los Angeles, California) automatic peptide synthe-
sizer and were purified to 495% homogeneity by reverse phase
HPLC, and peptide composition was confirmed by mass spect-
rometry and amino acid analysis. Stock peptide solutions were
prepared at 20 mg per mL in DMSO or at 2 mM in water. To con-
struct a peptide containing amino acid residues 62–74, additional
sequence from the 15–kDa form of granulysin was used to gen-
erate the 61–80 peptide so the length of this peptide would be
similar to the others in our study. Serine residues were also
substituted for the protein’s native cysteine residues to avoid for-
mation of disulfide linkages between peptides, these substitutions
are marked with italics. The sequences for the resulting peptides
are as follows: 1–35, GRDYRTSLTIVQKLKKMVDKPTQRSVS-
NAATRVSR; 36–70, TGRSRWRDVSRNFMRRYQSRVIQGLVAGE-
TAQQIS; 1–20, GRDYRTSLTIVQKLKKMVDK; 31–50, TRVSRT
GRSRWRDVSRNFMR; 16–35, KMVDKPTQRSVS NAATR VSR;
46–65, RNFMRRYQSRVIQGLVAGET; 61–80, VAGETAQQISEDLR.
Additionally, the valine residue at position 44 of peptide 31–50 was
substituted with a tryptophan, resulting in peptide 31–50v44w with
the sequence of TRVSRTGRSRWRD WSRNFMR. Also, this same
peptide sequence was synthesized with all D-type amino acids to
generate peptide D-31–50v44w.
Granulysin peptide derivatives were assembled via solid phase
peptide synthesis, using either an Applied Biosystems 433A or
Symphony (Rainin/Protein Technologies) automated peptide syn-
thesizer. Standard methods of Fmoc-based solid phase peptide
synthesis were applied using modules in the software packages
provided with the automated instrument. Rink amide resin and all
amino acid derivatives (D- and L-) were purchased from EMD Bio-
sciences/Novabiochem (San Diego, California). Peptide couplings
were achieved via activation as the HOBT ester using 2-(1H-ben-
zotriazole-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate
(HBTU, American Bioanalytical, Natick, Massachusetts). Cleavage
of the peptide from the solid phase resin was achieved with
a cocktail consisting of 90% TFA and 2% each of water,
triisopropylsilane, ethanedithiol, thioanisole, and phenol (all from
Sigma-Aldrich, Milwaukee, Wisconsin) for 2.5 h. Crude peptides
were purified to greater than 95% purity via C18 reversed phase
HPLC using acetonitrile–water–TFA eluant systems and lyophilized
to dryness. Peptide identity was confirmed by MALDI-TOF mass
spectrometry (Bruker Autoflex mass spectrometer, Bruker Dalton-
ics, Billerica, Massachusetts) in a matrix of a-cyanohydroxycin-
namic acid (CHCA, Sigma-Aldrich). Amino acid analysis (Molecular
Structure Facility at the University of California, Davis) was used to
confirm peptide composition and content.
An HSP70 peptide was synthesized and used as a control
peptide as previously described (Stenger et al, 1998; Ernst et al,
2000). HSP70 peptide is a good control since as it is of similar
length compared to our granulysin-derived peptides, and it is also
a self-peptide.
CFU assay The CFU assay was performed as described previously
(Ernst et al, 2000). P. acnes strain ATCC 6919 (American Type Cell
Culture (ATCC), Manassas, Virginia) was grown under anaerobic
conditions in Reinforced Clostridial Medium (Oxoid, Basingstroke,
England) for 2 d and collected in mid-log phase. The bacteria were
washed three times with the assay buffer, 10 mM sodium phos-
phate, pH 7.2, supplemented with 0.03% trypticase soy broth (TSB,
Becton-Dickinson, Cockeysville, Maryland), and enumerated by
applying a conversion factor of 7.5  107 bacteria per mL¼ 1 OD
unit at 600 nm. Various concentrations of granulysin or granulysin
peptides were incubated with 3.75  105 bacteria in a final volume
of 30 mL at 371C for 4 h. After incubation, 10-fold dilutions were
prepared and plated on solid media comprised of Brucella broth
(BD Biosciences, San Diego, California) with 5% sheep red blood
cells (Remel, Lenexa, Kansas), 0.5 mg per liter vitamin K, and 5.0
mg per liter hemin (Remel). Plates were incubated for 4 d at 371C
under anaerobic conditions, then individual colonies were counted
and the number of CFU per tube was calculated.
Electron microscopy P. acnes at a concentration of 2.08  107
bacteria per mL was suspended in 10 mM sodium phosphate
buffer pH 7.2 supplemented with 0.03% TSB and incubated with
20 mM granulysin peptides. Samples were then fixed for 30 min
with 2% gluteraldehyde in 1  PBS, pH¼ 7.35, room temperature,
then washed three times and suspended in 1 mL 1  PBS. Scan-
ning EM samples were filtered onto a micropore filter. The filters
with the sample on top were dehydrated in graded ethanol; 50%,
75%, 95%, and 100%—15 min in each, followed by similar trans-
fers in hexa-methyl-disilazane reagent; 50%, 75%, 95%–30 min
each followed by 100% hexa-methyl-disilazane reagent overnight.
The scanning EM samples were gold coated and then viewed and
photographed on a Cambridge Scanning electron microscope.
Transmission EM samples were dehydrated in graded ethanol as
above, embedded in Epon, and sectioned on Sorvall MT6000
(RMC, Tucson Arizona). Thin sections (75 mm) were stained with
uranyl acetate, viewed and photographed on Jeol XC100 at 80-kV.
E. coli killing assays Log phase cultures of E. coli strains TOP10
(Invitrogen, Carlsbad, California) and ATCC 55099 (negative for
proteases OmpT, DegP, and protease III) (ATCC) were diluted to
2  107 CFU per mL (¼ 2  test inoculum) in assay buffer (20%
trypic soy broth, 1 mM MgCl2, 50 mM NaHCO3, pH 7.4). A serial
dilution (1–64 mM final assay concentration) of the indicated gran-
ulysin peptides were prepared in 96-well microtiter plates in 50 mL
assay buffer. After addition of 50 mL 2  test inoculum the plates
were incubated for 24 h at 371C in an ambient air incubator. The
sample was diluted 1:35 with PBS. To determine the MBC, 10 mL of
the diluted sample was spotted on a tryptic soy broth agar plate and
incubated at 371C overnight. MBC was defined as the lowest pep-
tide concentration without any visible growth on the typtic soy broth
agar plate (equals 4log 4 reduction of the initial test inoculum).
Antibiotics The effect of both Clindamycin and Tetracyclin (Si-
gma, St Louis, Missouri) against P. acnes was determined with a
qualitative CFU assay which involved plating 20 mL of each sample
(P. acnes with antibiotics or granulysin peptide) on the solid media
and quantifying existing colonies using CFU assay as described
above in detail.
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Microcomedone assay After informed consent was obtained,
comedones were collected from human volunteers using pore
cleansing strips (Jergens, Cincinnati, Ohio) according to the
Declaration of Helsinki Principles and the Institutional Review Board
at UCLA. Individual plugs were removed from the strips with a fine
point tweezer and pooled in a microfuge tube. These were then
resuspended in 200 mL of assay medium (20% tryptic soy broth, BD
Microbiology Systems, Sparks, Maryland) until the particulate ma-
terial was broken up into a colloidal suspension as determined by
light microscopy. Then, 10 mL of this suspension was combined with
either 10 mL of peptide solution or 10 mL of distilled water (negative
control). These were then incubated for 2.5 h at 371C in an ambient
air incubator. A serial dilution of each sample was prepared and 15
mL of each dilution was spotted on a Brucella blood agar plates and
incubated as previously described. Digital images of individual
plates were taken using an Alpha Innotech Chemimager 5500 (Alpha
Innotech, San Leandro, California) and bright light illumination. The
CFU per mL was determined by counting.
Primary human monocyte isolation and stimulation Peripheral
human blood was drawn from normal healthy volunteers into he-
parinized tubes according to a protocol approved by the Institu-
tional Review Board at UCLA. PBMC were then isolated on Ficoll–
Paque gradients (Pharmacia, Piscataway, New Jersey) and plated
(5  105 per well) in 96-well plates for 2 h in 1% FCS (Omega
Scientific, Tarzana, California). Non-adherent cells were removed
by washing three times with RPMI media, leaving adherent cells.
Adherent monocytes were cultured in 10% FCS with or without
granulysin peptides for 1 h then P. acnes sonicate was added to
culture for 24 h at 371C.
Monocyte supernatants were harvested and assayed for IL-
12p40 using cytokine-specific, commercially available antibody
pairs in a standard sandwich ELISA (Biosource International,
Camarillo, California, or BD PharMingen, San Diego, California).
Capture antibodies were coated to 96-well EIA/RIA plates (Costar,
Corning, New York) and detection was achieved by incubating with
biotinylated antibodies followed by Immunopure HRP-conjugated
streptavidin (Pierce, Rockford, Illinois) and the ABTS Microwell
Peroxidase Substrate System (Kirkegaard & Perry Laboratories,
Gaithersburg, Maryland). The absorbance at 405 nm was read us-
ing a microtiter plate reader, and cytokine concentrations were
calculated from a standard curve of recombinant cytokine (Bio-
source or Pharmingen). Supernatants were assayed for other
cytokines using Pierce SearchLight Multiplex Cytokine array serv-
ices (Pierce Biotechnology, Woburn, Massachusetts). For the Mul-
tiplex arrays, for each separate monocyte stimulation experiment,
triplicate samples from 96-well plates were pooled to provide suf-
ficient sample volume at appropriate concentration for analysis.
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